Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture surged 18% after fiscal Q4 revenue of $18.7B exceeded its $17.8B-$18.4B guidance and the $18.3B consensus, while EPS of $3.29 also beat expectations. Synopsys rose more than 8% after targeting 2027 revenue of $11.1B-$11.2B and announcing an OpenAI partnership; Vicor climbed nearly 10% after raising Q3 revenue-growth guidance to more than 30% from at least 20%. Major negative moves included Liquidia, down 15% after a patent-infringement ruling, Sigma Lithium, down 16% following a production suspension, and Corteva's remaining business, down 84% after the Vylor spinoff.

Analysis

ACN’s rerating is only durable if its next bookings disclosure demonstrates that AI-led work is additive rather than a substitution of traditional implementation labor. The key second-order risk is margin: generative AI can raise delivery productivity but also gives clients leverage to demand lower billing rates. Over the next 1-3 months, watch consulting bookings, managed-services renewal pricing, and utilization; sustained double-digit bookings growth would support further multiple expansion, while a utilization decline without margin guidance upside would make the initial move vulnerable.

CEG’s strategic value is rising as hyperscalers seek firm, carbon-free power rather than intermittent renewable supply. The relevant debate is not merely contracted revenue but the opportunity cost of dedicating scarce nuclear output to a single counterparty: long-duration contracts can lower cash-flow volatility and financing costs, but may cap upside if power prices or capacity values reprice sharply higher. This supports CEG relative to merchant generation peers over 6-18 months, while making regulatory approvals, construction execution, and the implied contract economics the near-term swing factors.

UTHR’s litigation result improves the durability of a high-margin orphan-drug cash-flow stream and should shift investor focus from competitive erosion to capital allocation and pipeline execution. Conversely, LQDA now faces a binary path dependent on appeal, product differentiation, and any settlement structure; its equity can remain impaired even if the underlying therapy retains clinical value. CTVA’s apparent price dislocation following the separation should not be read as an operating signal until the value of distributed shares, cost allocations, stand-alone leverage, and post-spin trading basis are reconciled; this is a likely mechanical-event setup rather than an immediate directional short.

Key Decisions for Investors

• Buy UTHR on consolidation rather than chase the legal-news gap; target a 6-12 month hold. The thesis is lower near-term competitive-risk discounting and continued cash generation. Exit if an appellate stay, adverse appeal ruling, or management guidance indicating material market-share loss reopens the competitive threat.
• Express AI-infrastructure demand through a long SNPS / short CDNS pair over 3-6 months, sized market-neutral. SNPS has a clearer opportunity to monetize expanded design complexity, but require quarterly evidence of backlog conversion and operating-margin preservation; close the pair if SNPS revenue growth fails to outpace CDNS for two consecutive reports.
• Maintain a 6-18 month CEG overweight versus merchant-power exposure such as VST, but do not add aggressively before contract-price, capex, and regulatory details are disclosed. A more attractive entry follows any pullback tied to financing concerns; thesis fails if incremental nuclear capacity requires returns materially below CEG’s cost of capital or if power-market policy undermines capacity pricing.
• Avoid directional CTVA trading until the spin distribution ratio and pro forma financials permit calculation of combined pre-spin value. Create an event-driven alert for a persistent 10%+ discount between the stub plus distributed security and the pre-separation reference value after normal settlement; only then evaluate a convergence trade.
• Treat LQDA as a short-on-strength or avoid rather than a fresh momentum short after the gap. Any settlement granting commercially meaningful launch rights, or a court order staying restrictions pending appeal, is a high-convexity squeeze risk; use defined-risk options if liquidity permits.